RNA Interference Markets

RNA Interference Markets

Since its discovery, the naturally occurring RNA (ribonucleic acid) interference effect has been acclaimed as the most exciting technical breakthrough in biological research in the last decade. Some industry analysts predict that RNA interference (RNAi) may even surpass PCR as a top technology. RNAi allows scientists to silence the expression or effect of a gene under study. This is known as gene knockdown. This field has rapidly emerged as a fast-growing new market. The purpose of this TriMark Publications report is to review the market for RNAi testing equipment and supplies. RNAi is a mechanism in molecular biology where the presence of certain fragments of double-stranded RNA (dsRNA) interferes with the expression of a particular gene which shares a similar sequence with the dsRNA. This study defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence market size and growth for RNAi testing.

The main objectives of this study are to:

1) understand the different sectors of RNAi testing market and to look at a description of the instruments, reagents and supplies marketed by major companies in each segment;

2) obtain a complete understanding of the individual RNAi-testing platforms—from basic principles to clinical applications;

3) discover feasible market opportunities by identifying high-growth applications in different analytical diagnostic areas, with a focus on the biggest and expanding markets;

4) focus on global industry developments and trends through an in-depth analysis of the major world markets for RNAi measurement technology, including growth forecasts;

5) present market figures related to the current value of RNAi testing, market projections, market share, key players and sector growth rates.

1. Overview

1.1 Objectives

1.2 Scope

1.3 Methodology

1.4 Executive Summary

2. RNA Interference (RNAi)

2.1 Introduction

2.2 Overview of RNA Interference

2.2.1 Classes of Small RNAs: siRNA, rasiRNA and miRNA

2.2.2 Mechanism of RNAi In Vivo

2.3 Glossary

2.4 What Areas of Research Does RNAi Impact?

2.4.1 RNAi Technology in Life Sciences Research, Drug Discovery and Development

3. Technology Trends in RNAi Space

3.1 Overview

3.2 End-User Segmentation

3.3 Technologies for Inducing RNAi

3.3.1 Methods for Detecting Gene Silencing

3.3.2 Libraries of siRNAs/shRNAs to Knockdown Genes En Masse

3.3.2.1 Publicly Available Largescale Mammalian RNAi Libraries

3.3.2.2 The RNAi Consortium (TRC)

3.3.3 Comparison of Strategies for Target Validation

3.3.3.1 Market Shifts in RNAi Space: Where Is It Headed?

3.3.4 miRNA-Based RNAi: Leading Edge of RNAi Space

3.3.4.1 Biological Function of miRNAs

3.3.4.2 Role of miRNAs in Cancer

3.3.4.3 Role of miRNAs in Human Cancer

3.4 SWOT Analysis of Technologies and Vendors in RNAi Space

4. RNAi Market Analysis

4.1 Overview

4.2 Market Data Collection and Respondent Pool

4.2.1 Respondent Pool Characteristics

4.3 RNAi Technologies/Products in Research Applications

4.4 RNAi Technologies/Products: Market Shares (Quantitative)

4.5 Quantitative Metrics of RNAi Usage: Market Opportunity and Growth

4.5.1 Growth of Various Segments in RNAi Space

4.5.2 Product Formats and Representation in RNAi Marketplace

4.6 RNAi Marketplace: Challenges, Unmet Needs and Drivers

4.6.1 Unmet Needs in RNAi Space

4.6.2 RNAi Market: Qualitative Growth Drivers

5. The RNAi Landscape

5.1 Overview

5.2 Market Segmentation of RNAi and Segment Characteristics

5.3 Quantitative Market Opportunities in RNAi Space

5.3.1 Opportunities in miRNA Space

5.3.2 Opportunities in siRNA/shRNA Space

5.4 RNAi Product Offerings and Associated Business Models

6. Company Profiles

6.1 Actigenics

6.2 Alnylam Pharmaceuticals

6.3 Amaxa

6.4 Ambion

6.5 Asuragen

6.6 B-Bridge International

6.7 Benitec

6.8 Bio-Rad Laboratories

6.9 BioVentures

6.10 Cenix BioScience

6.11 Clontech

6.12 CytRx

6.13 Dharmacon

6.14 DNAVision

6.15 Exiqon

6.16 GeneCopoeia

6.17 GenoSensor

6.18 IDT

6.19 Invitrogen

6.20 InvivoGen

6.21 Isis Pharmaceuticals

6.22 Nucleonics

6.23 Open Biosystems

6.24 OriGene

6.25 Panomics

6.26 Promega

6.27 QIAGEN

6.28 Roche

6.29 RZPD

6.30 Sigma-Aldrich

6.31 Sima Therapeutics

6.32 System Biosciences

INDEX OF TABLES

Table 2.1: Advantages/Disadvantages of siRNAs & shRNAs as Inducers of RNAi in Mammalian Cells

Table 2.2: Suppliers of Enabling Technologies and Tools in RNAi Space

Table 2.3: Suppliers of siRNA/shRNA Products (by Product/Service Class)

Table 3.1: Currently Utilized Technologies for Inducing RNAi-Mediated Knockdown

Table 3.2: Comparison of mRNA Detection Technologies

Table 3.3: Characteristics of Various Mouse and Human RNAi Libraries Publicly Available

Table 3.4: Comparison of Formats for Library-Based Gene Knockdown

Table 3.5: Strategies for Target Validation by Pharma/Biotech: RNAi and Others

Table 3.6: SWOT Analysis of siRNA Oligonucleotides

Table 3.7: Transfection Reagents (Lipid-Mediated Delivery)

Table 3.8: shRNA Plasmid Constructs

Table 3.9: shRNA Pooled Libraries or Arrayed Collections (Retroviral/Lentiviral Delivery)

Table 5.1: RNAi Market Segmentation and Research Settings

Table 5.2: Segment 1: Basic Life Science Research Utilizing RNAi Tools and Technologies

Table 5.3: Segment 2: RNAi for Drug Discovery and Development

Table 5.4: Segment 3: RNAi Research for Development of RNAi Therapeutics

Table 5.5: Segment 4: RNAi Fee-for-Service Business

Table 5.6: Grants Awarded and Research Spending in miRNA Space, 2005-2007

Table 5.7: RNAi Opportunity and Market Size: Quantitative Model, 2006-2009

INDEX OF FIGURES

Figure 2.1: The miRNA Processing Pathway

Figure 2.2: Mechanisms of Small RNA-induced Gene Regulation

Figure 2.3: Growth of Scientific Publications Addressing miRNAs, 2001-2006

Figure 3.1: End-User Segmentation of RNAi Space

Figure 4.1: Geographical Breakdown of RNAi End-User Survey Respondents

Figure 4.2: Affiliation of RNAi End-User Survey Respondents

Figure 4.3: Utilization of RNAi Technologies/Products by Respondent Pool

Figure 4.4: RNAi Utilization Period: Breakdown of Respondent Pool

Figure 4.5: Research Applications Using RNAi Technologies/Products

Figure 4.6: Types of RNAi Technologies Currently Utilized

Figure 4.7: RNAi Technologies Most Commonly Utilized Currently by End-Users

Figure 4.8: Types of RNAi Technologies: Expected Use in Six to 18 Months

Figure 4.9: Evolution of Market Shares of RNAi-Inducing Technologies

Figure 4.10: Number of Experiments Involving RNAi Conducted Per Week

Figure 4.11: Range of Research Dollars Spent Monthly on RNAi Research

Figure 4.12: RNAi Experiment Throughput Correlated with Type of RNAi Technology Used

Figure 4.13: Growth/Decline Rate of RNAi Marketplace Segments (Six to 18 Months)

Figure 4.14: Product Formats Utilization for RNAi Research: Current and Six to 18 Months

Figure 4.15: Companies Offering Product Formats for Currently Used RNAi Products

Figure 4.16: RNAi Product Offerings/Formats Use: (Projections--Six to 18 Months)

Figure 4.17: Percentage Change of RNAi Product Offerings/Formats (Six to 18 Months)

Figure 4.18: Key Challenges Faced by End-Users in RNAi Space

Figure 4.19: Unmet Needs in RNAi Space Ranked by Importance to End-Users

Figure 5.1: Growth and Evolution of miRNA Space

Figure 5.2: Elements of RNAi Value Chain

Figure 5.3: Growth and Evolution of RNAi (siRNA/shRNA) Space

Figure 5.4: Market Revenues Based on Components of siRNA Experimental Paradigm